Constructive Bio
Generated by Meeveem AI
"Engineering biology to manufacture peptide and protein therapeutics with chemistries beyond nature."
About Constructive Bio
Constructive Bio is a Cambridge biotechnology company that reprograms living cells to manufacture peptides and proteins containing non-canonical amino acids, extending biology beyond its standard 20 building blocks. Its BioForge platform combines the Syn61 recoded organism with engineered translation and fermentation to support production at industrial scale.
Launched in 2022 to commercialise Professor Jason Chin’s research at the MRC Laboratory of Molecular Biology, the company develops technology for pharmaceutical and industrial partners. Its therapeutic programmes include site-specific antibody-drug conjugates, engineered cytokines, covalent biologics and oral peptides. The team brings together genetic code expansion, protein engineering and biological manufacturing expertise, with more than 60 team members reported on its website.
Science and engineering together
Constructive Bio recruits scientists, engineers and builders across synthetic biology, protein engineering and biomanufacturing. Its work links the design of new chemical building blocks with the engineering needed to turn biological discoveries into manufactured products.
From platform to partnerships
The company works with pharmaceutical and biotechnology partners on protein and peptide therapeutics. Its commercial and scientific teams support partnerships, licensing and the development of molecules using its expanded chemistry and manufacturing platform.
51
Team Members
2022
Founded
Biotechnology
Sector
On-Site
Work Environment